Compare FINW & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINW | SLN |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 116 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.7M | 236.2M |
| IPO Year | 2021 | N/A |
| Metric | FINW | SLN |
|---|---|---|
| Price | $14.50 | $6.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | 20.8K | ★ 184.1K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.51 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $160.48 | N/A |
| Revenue Next Year | $35.27 | N/A |
| P/E Ratio | $72.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.82 | $4.19 |
| 52 Week High | $22.49 | $8.40 |
| Indicator | FINW | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 52.19 |
| Support Level | $12.82 | $5.76 |
| Resistance Level | $17.39 | $7.53 |
| Average True Range (ATR) | 0.49 | 0.58 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 93.01 | 66.18 |
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.